<DOC>
	<DOCNO>NCT00478361</DOCNO>
	<brief_summary>This phase II trial study well give gemcitabine , paclitaxel , doxorubicin together pegfilgrastim work treat patient metastatic unresectable bladder cancer urinary tract cancer kidney dysfunction . Drugs use chemotherapy , gemcitabine , paclitaxel , doxorubicin , work different way stop growth tumor cell , either kill cell stop dividing . Colony stimulate factor , pegfilgrastim , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . Giving combination chemotherapy together pegfilgrastim may kill tumor cell . Chemotherapy drug may different effect patient change kidney function .</brief_summary>
	<brief_title>Gemcitabine , Paclitaxel , Doxorubicin Metastatic Unresectable Bladder Cancer With Decreased Kidney Function</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Assess efficacy gemcitabine hydrochloride , paclitaxel , doxorubicin hydrochloride , pegfilgrastim , term response rate , patient metastatic unresectable transitional cell carcinoma bladder urinary tract renal insufficiency . SECONDARY OBJECTIVES : I. Assess safety tolerability regimen patient . II . Determine median time progression patient treat regimen . III . Determine median survival duration patient treat regimen . IV . Assess safety efficacy pegfilgrastim patient . OUTLINE : This multicenter study . Patients receive doxorubicin hydrochloride intravenous ( IV ) 20 minute , paclitaxel IV 60 minute , gemcitabine hydrochloride IV 90 minute , pegfilgrastim subcutaneously day 1 . Treatment repeat every 14 day 9 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologically cytologically confirm transitional cell carcinoma ( TCC ) bladder , urethra , upper urinary tract Mixed TCC variant histology ( i.e. , small cell , squamous cell , adenocarcinoma , sarcoma ) allow present &lt; 50 % biopsy specimen Patients must sign informed consent indicate aware investigational nature study , keep policy institution . Measurable disease : may include radiographic detection metastasis lymph node ( &gt; = 1.5 cm ) liver lung ( &gt; = 1.0 cm ) OR pelvic mass palpable examination anesthesia Creatinine clearance &lt; 60 mL/min ; renal insufficiency require hemodialysis ; renal insufficiency reversible patient tumor confine primary site ( i.e. , potentially resectable neoadjuvant chemotherapy ) Zubrod performance status 02 Platelet count &gt; 100,000/mm^3 Absolute granulocyte count &gt; 1,500/mm^3 Bilirubin = &lt; 2.0 mg/dL AST ALT = &lt; 2 time upper limit normal LVEF &gt; 40 % OR normal EKG history cardiac disease All patient must evaluate Department Genitourinary Medical Oncology M. D. Anderson Cancer Center participate CCOP center prior sign inform consent . No prior systemic chemotherapy include , adjuvant neoadjuvant therapy Prior intravesicular chemotherapy allow No brain metastases Not pregnant nursing No severe uncontrolled infection No New York Heart Association class IIIIV congestive heart failure , unstable angina , history myocardial infarction within past 6 month No peripheral neuropathy &gt; = grade 2 No persistently uncontrolled diabetes mellitus No chronic liver disease No HIV positivity No malignancy except nonmelanoma skin cancer unless diseasefree past 3 year No overt psychosis , mental disability , condition would preclude give informed consent No known sickle cell disease No uncontrolled severe hypertension Renal insufficiency require hemodialysis renal insufficiency reversible patient tumor confine primary site ( i.e. , potentially resectable neoadjuvant chemotherapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>